Connect with us
Prague Gaming & TECH Summit 2025 (25-26 March)

Fintech PR

Pancreatic Cancer Treatments Poised for Major Advances in 2024

Published

on

pancreatic-cancer-treatments-poised-for-major-advances-in-2024

FN Media Group Presents USA News Group News Commentary

VANCOUVER, BC, Feb. 7, 2024 /PRNewswire/ — USA News Group  –  One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer. As well, the deadly disease showed pancreatic cancer rates rising faster among women, causing increased alarm amongst doctors. Thankfully, 2023 also gave a lot of hope in terms of new treatments for the market that could reach US$36 billion by 2036, such as a potential mRNA vaccine, and other developments from biotech companies to lead into 2024, like Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Incyte Corporation (NASDAQ:INCY), Tango Therapeutics, Inc. (NASDAQ:TNGX), RayzeBio, Inc. (NASDAQ:RYZB) and its buyer Bristol-Myers Squibb Company (NYSE:BMY).

After closing out 2022 with another fast track designation, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) and its flagship asset pelareorep continues to make strides in the battle against pancreatic cancer. This recognition came after pelareorep plus atezolizumab with gemcitabine and nab-paclitaxel achieved an impressive objective response rate (ORR) of 69%. The results were enough to garner the support of the Pancreatic Cancer Action Network (PanCAN), who selected pelareorep to receive the US$5 million Therapeutic Accelerator Award.

“2023 was an outstanding year for Oncolytics and the development of pelareorep as a potential cancer therapy,” said Dr. Matt Coffey, President and CEO of Oncolytics. “To date, we have studied pelareorep in more than 1,100 patients, and it has been shown to be well-tolerated with mild side effects. We believe our cash balance and strong data, supported by our active business development program, position us well for 2024.”

Most recently, Oncolytics added accomplished biopharmaceutical executive Pat Andrews to its Board of Directors. She comes with a track record of success in corporate strategy, first-in-class and first-for-the-company new product commercializations and business development, and a resume that includes 17 years with Pfizer leading a $900-million portfolio at the time, and later serving as CEO of Sumitomo Pharma Oncology (SMP), and as the Chief Commercial Officer for Incyte Corporation (NASDAQ:INCY), where she led the company through the launch of Jakafi, Incyte’s first commercial product.

“I am honored to join the Oncolytics board at this exciting time for the organization as it advances pelareorep toward registrational studies,” said Ms. Andrews. “Promising recent results from the BRACELET-1 and GOBLET studies suggest that pelareorep has the potential to make an important contribution to cancer care, and I look forward to working with my fellow board members in addition to Dr. Coffey and the Executive Team to execute Oncolytics’ clinical and corporate development plans.”

Andrews’s previous employer Incyte Corporation (NASDAQ:INCY) also continues to be active in the pancreatic cancer space itself. Like Oncolytics Biotech, Incyte is also involved with PanCAN in bringing potentially pioneering treatment options to patients.

Now, the market is watching out for the potential future approval of Incyte’s INCA-33890 for pancreatic cancer, which is currently in Phase I. INCA-33890 is a novel PD-1x TGFbR2 bispecific antibody designed to conditionally antagonize TGF signaling in primary immune cells co-expressing PD-1.

Through a licensing deal with Swedish pharmaceutical company Medivir, Tango Therapeutics, Inc. (NASDAQ:TNGX) received FDA clearance on its Investigational New Drug application for TNG348 back in September 2023. Now, in early 2024, Tango has dosed the first patient for the drug in a phase 1/2 clinical study. Tango licensed TNG348 from Medivir back in 2020.

TNG348 is a novel USP1 inhibitor for the treatment of BRCA1/2-mutant and other homologous recombination deficiency (HRD)+ cancers. HRD+ cancers, including BRCA1/2 mutations, represent 5% of pancreatic cancers.

Advertisement

“The preclinical data generated by Tango for TNG348 is promising and dosing the first patient in a clinical study is encouraging for patients with HRD+ cancers,” said Jens Lindberg, CEO of Medivir. “The efforts undertaken by Tango to develop TNG348 into a clinical-staged drug are impressive and we will continue to follow the clinical development of TNG348 with great anticipation.”

Closing out 2023, Bristol-Myers Squibb Company (NYSE:BMY) struck a deal for roughly $4.1 billion to buy RayzeBio, Inc. (NASDAQ:RYZB), with the highlight of the deal being RYZ101, which is being tested in late-stage studies for a rare type of pancreatic cancer. It’s a drug that uses radioactive particles to kill tumor cells.

“[The RayzeBio acquisition] further strengthens our growth opportunities in the back half of the decade and beyond,” said Chris Boerner, newly-appointed CEO of BMY.

“Acquiring RayzeBio’s differentiated actinium-based radiopharmaceutical platform will establish Bristol Myers Squibb’s presence in one of the most promising and fastest-growing new modalities for the treatment of patients with solid tumors – delivering radioactive payloads to cancer cells in a targeted manner,” added Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer, Drug Development of Bristol Myers Squibb. “In addition, RayzeBio’s platform has the potential to be a significant IND engine, generating several therapeutic candidates in the future by leveraging our global drug development capabilities and infrastructure.”

Article Source: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ 

Article Source: 

USA News Group

http://USAnewsgroup.com [email protected]

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Advertisement

USA News Group is Source of all content listed above.  FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein.  The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM.  FNM is not liable for any investment decisions by its readers or subscribers.  FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM was not compensated by any public company mentioned herein to disseminate this press release.

This release contains “forward-loking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Media Contact Information:

FN Media Group, LLC
Media Contact e-mail:  
[email protected]
U.S. Phone: +1(954)345-0611

View original content:https://www.prnewswire.co.uk/news-releases/pancreatic-cancer-treatments-poised-for-major-advances-in-2024-302055604.html

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

BitGo Appoints Brett Reeves as Head of European Sales Complementing his Go Network Role

Published

on

bitgo-appoints-brett-reeves-as-head-of-european-sales-complementing-his-go-network-role

PALO ALTO, Calif., Jan. 15, 2025 /PRNewswire/ — BitGo, the leading digital asset infrastructure solutions provider since 2013, is pleased to announce that Brett Reeves has been appointed Head of European Sales, a role he takes on in addition to his existing position as Head of Go Network. His new title is Head of Go Network and European Sales.

Brett joined in May 2024 and has since then overseen the expansion of BitGo’s presence in Europe, which includes onboarding new clients and partners and expanding the volume and scope of business across multiple jurisdictions within the European Union and UK.

Brett Reeves, Head of Go Network and European Sales, said:

“Since joining BitGo last year, it has been an intense and rewarding journey. Alongside growing the business our focus has been on obtaining the necessary licenses to achieve MiCA compliance, ensuring we are fully prepared for a comprehensive rollout of our Custody, Wallets, Staking, Trading and Financing services across Europe. With a growing team and increasing demand for secure, well-regulated digital asset solutions, we are highly optimistic about the opportunities 2025 holds for us.”

Brett has twenty years’ experience in the financial services industry having worked at Citibank, Nomura and Standard Chartered Bank. His background includes working within Prime Brokerage and OTC teams within the FX and interest rates markets. Most recently Brett was the Head of Business Development at the Bequant, a regulated digital asset Prime Broker.

About BitGo
BitGo is the leading infrastructure provider of digital asset solutions, offering custody, wallets, staking, trading, financing, and settlement out of regulated cold storage. Founded in 2013, BitGo is the first digital asset company to focus exclusively on serving institutional clients. BitGo is dedicated to advancing a digital financial services economy that is borderless and accessible 24/7. With multiple Trust companies around the world, BitGo is the preferred security and operational backbone for more than 1,500 institutional clients in 50 countries, including many of the world’s top brands, cryptocurrency exchanges, and platforms. BitGo also secures approximately 20% of all on-chain Bitcoin transactions by value and is the largest independent digital asset custodian.

W: https://www.bitgo.uk/
L: https://www.linkedin.com/company/bitgo/
X: https://x.com/BitGo

View original content:https://www.prnewswire.co.uk/news-releases/bitgo-appoints-brett-reeves-as-head-of-european-sales-complementing-his-go-network-role-302350962.html

Continue Reading

Fintech PR

Markel elevates Wanshi Lin to newly created Head of Singapore position

Published

on

markel-elevates-wanshi-lin-to-newly-created-head-of-singapore-position

SINGAPORE, Jan. 15, 2025 /PRNewswire/ — Markel, the insurance operations within Markel Group Inc. (NYSE: MKL), today announced that Wanshi Lin has been appointed as the Head of Singapore, effective immediately.

In this newly created position, Lin will oversee the company’s underwriting team in Singapore and spearhead business planning and market engagement on the company’s Lloyd’s Singapore platform. The establishment of a new leadership role in Singapore is demonstrative of Markel’s ongoing commitment to expanding its Asia Pacific operations and underwriting capabilities.

Lin will report to Christian Stobbs, Managing Director – Asia Pacific, in her new capacity.

Stobbs commented: “I’m thrilled about the energy and innovative ideas Wanshi will bring to this pivotal role. Singapore is our largest marketplace in the region for specialty products, and I’m confident that, under her leadership, we’ll further enhance our relationships with brokers and clients while building on the strong momentum achieved in recent years.”

Kevin Leung, Chief Underwriting Officer – Asia Pacific, adds: “It’s a delight to see Wanshi progress to take on this role. Her extensive experience, strategic insight and understanding of the Singapore market will be instrumental in strengthening our commitment to providing underwriting excellence to this important regional hub.”

Lin joined Markel in 2018 as an Assistant Underwriter – Marine, and since 2023 has been Senior Underwriter – Marine. Prior to Markel, Lin was Assistant Vice President at Marsh Singapore.

About Markel

We are Markel, a leading global specialty insurer with a truly people-first approach. As the insurance operations within Markel Group Inc. (NYSE: MKL), we operate the Markel Specialty, Markel International, and Markel Global Reinsurance divisions, as well as State National, our portfolio protection and program services operations, and Nephila, our insurance-linked securities operations. Our broad array of capabilities and expertise allow us to create intelligent solutions for the most complex risk management needs. However, it is our people – and the deep, valued relationships they develop with colleagues, brokers and clients – that differentiates us worldwide.

Markel logo

Photo – https://mma.prnewswire.com/media/2597760/Markel_Wanshi_Lin.jpg
Logo – https://mma.prnewswire.com/media/2090808/Markel_primary_logo_Logo.jpg 

Cision View original content:https://www.prnewswire.co.uk/news-releases/markel-elevates-wanshi-lin-to-newly-created-head-of-singapore-position-302350760.html

Continue Reading

Fintech PR

FinVolution’s SVP Ming Gu speaks at Asian Financial Forum, highlighting opportunities in CreditTech for Southeast Asia’s underserved

Published

on

finvolution’s-svp-ming-gu-speaks-at-asian-financial-forum,-highlighting-opportunities-in-credittech-for-southeast-asia’s-underserved

HONG KONG, Jan. 15, 2025 /PRNewswire/ — FinVolution Group (NYSE: FINV), a leading fintech service provider in the pan-Asian region, reaffirmed its commitment yesterday to advancing financial inclusion through cutting-edge credit technology and strategic partnerships at the Asian Financial Forum 2025 in Hong Kong.

 

The Fintech Showcase at AFF 2025

Dr. Ming Gu, Senior Vice President of FinVolution Group, shared his insights on how fintech innovation is transforming access to credit for underserved populations in Southeast Asia.

“Fintech is creating new pathways for underserved populations to access credit and financial support, empowering them to invest in their futures,” he said at a thematic workshop on the future of fintech in Southeast Asia.

Driving financial inclusion through innovation

Gu emphasized FinVolution’s mission to bridge the gap between financial institutions and underserved communities by leveraging advanced credit technology.

The company has built its business around serving young workers and small business owners from grassroots backgrounds, whose financial needs are often overlooked by traditional banks and other financial institutions.

Through user-friendly digital lending platforms and collaborations with local partners, FinVolution has supported over 6 million borrowers and facilitated loans exceeding US$3 billion in its markets outside China as of Q3 2024.

FinVolution’s AI-powered tools enable financial institutions to better assess creditworthiness, particularly for those without traditional credit histories, Gu explained.

Opportunities and challenges in Southeast Asia’s market

Gu highlighted Southeast Asia’s potential as a key growth market for fintech, driven by its young population, e-commerce growth, and credit-driven consumption habits.

Advertisement

“Very few regions in this world can meet all these criteria,” he said, highlighting the underpinnings of Southeast Asia’s ascent as a fintech powerhouse. “Digital lending always goes hand in hand with the growth of e-commerce.”

“The number one factor driving financial inclusion and literacy is GDP per capita,” Gu said. “Fintech and other technologies serve as a tool to facilitate this process, but it is GDP per capita that remains the cornerstone of development.”

For instance, Indonesia’s ambitious Golden Indonesia 2045 Vision aims to accelerate the nation’s economic growth by at least 5% annually over the next two decades.

This initiative reflects the nation’s commitment to fostering financial inclusion and leveraging technology as a catalyst for sustainable progress.

Indonesia is the place to watch over the next five to 10 years,” Gu added. “We are very bullish on Southeast Asia.”

Symbiotic relationship with regulators and financial partners

Despite these opportunities, challenges such as the lack of credit histories and increasing fraud risks persist, threatening the future of fintech in this region.

FinVolution combats these issues with advanced proprietary risk management systems and fraud prevention technologies.

Gu stressed the collaboration with regulators and financial institutions in creating a robust and inclusive financial ecosystem.

FinVolution itself adheres to stringent regulatory standards, securing necessary licenses and aligning with local laws. This endeavor coincides with steady improvements to Southeast Asia’s regulatory stringency in recent years, which are credited for creating an environment conducive to fintech innovation.

Advertisement

“I believe a symbiotic relationship between regulators and fintechs like us is crucial to Southeast Asia’s rise as a key global fintech hub,” Gu noted.

With over 100 financial institution partners, including digital banks and consumer finance companies, FinVolution provides end-to-end credit tech solutions that streamline processes and expand outreach.

FinVolution Group remains dedicated to driving financial inclusion and innovation in Southeast Asia. With a focus on technology and collaboration, the company aims to empower individuals and communities while fostering a thriving fintech ecosystem in the region.

Photo – https://mma.prnewswire.com/media/2598520/xinye_photo_1.jpg
Photo – https://mma.prnewswire.com/media/2598521/20250115135952.jpg
Logo – https://mma.prnewswire.com/media/2596551/FinVolution_intl_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/finvolutions-svp-ming-gu-speaks-at-asian-financial-forum-highlighting-opportunities-in-credittech-for-southeast-asias-underserved-302351545.html

Continue Reading
Advertisement
Advertisement European Gaming Congress 2024

Latest news

Trending